The growing popularity of GLP-1 receptor agonists, especially semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), both of which are FDA-approved for type 2 diabetes and/or obesity and, has been accompanied by considerable social media attention and discussion, from which thorough analyses of user-generated data have emerged highlighting reductions in alcohol-seeking motivation, decreased drinking behavior, and altered subjective responses to alcohol (Arillotta et al
They can assess the severity of your symptoms and adjust your treatment plan accordingly
Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al
[3] These clinical benefits, however, remain contingent upon intact NO release from nitrergic nerves or endothelial cells, so individual responses may vary
At Morgan & Morgan, we are dedicated to protecting consumers from harmful drugs and holding manufacturers accountable for their negligence